Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Novel Trial Designs and Modern Research Efforts Drive RCC Treatment Advances

November 4th 2022

Eric Jonasch, MD, discusses key clinical trials that are paving the way for improved treatment sequencing in renal cell carcinoma and the prospective benefits of neoadjuvant cabozantinib in nonmetastatic clear cell renal cell carcinoma.

Systemic Therapy in the Treatment of Non-Clear Cell RCC: The Evolving Landscape

November 3rd 2022

Moving on to discuss the management of non–clear cell renal cell carcinoma, panelists consider cornerstone treatment options in this setting.

Advanced Clear Cell RCC: Optimal Selection and Sequencing of Second-Line Therapy

November 3rd 2022

Comprehensive insight to the optimal selection and sequencing of therapy for advanced clear cell RCC in the second-line setting and beyond.

Treatment Options for Advanced Clear Cell RCC in the Second-Line and Beyond

October 27th 2022

Centering their discussion on the second-line setting, expert oncologists review mainstay second-line therapies for advanced clear cell RCC.

Is There a Role for Adjuvant Therapy in Advanced Clear Cell RCC?

October 27th 2022

Expert perspectives on key clinical trials studying first-line adjuvant therapy in patients with advanced clear cell renal cell carcinoma.

Immunotherapy-Based Combinations Remain the Focus of Frontline Treatment in Metastatic RCC

October 20th 2022

Rana R. McKay, MD, discusses the evolution of frontline treatment options for metastatic RCC, and the key clinical trials that have shifted the treatment paradigms in metastatic castration-resistant prostate cancer, nonmetastatic castration-resistant prostate cancer, and advanced prostate cancer.

First-Line Therapy in Advanced Clear Cell RCC: Novel Triplet Regimens

October 20th 2022

Focusing on novel first-line triplet therapy combinations, panelists consider which regimens may find a role in the management of advanced clear cell RCC.

First-Line Therapy in Advanced Clear Cell RCC: Novel Doublet Regimens

October 20th 2022

An expert panel reviews novel first-line doublet therapies being studied in patients with advanced clear cell renal cell carcinoma.

Dr. Xu on Future Developments in Kidney Cancer

October 17th 2022

Wenxin Xu, MD, discusses future considerations for the treatment of patients with kidney cancer. 

Advanced Clear Cell RCC: Quality of Life Data in First-Line Clinical Trials

October 13th 2022

Before closing out their review of mainstay combination therapy in the first-line setting of advanced clear cell RCC, panelists reflect on available quality of life data.

Treating Patients with Clear Cell RCC with Brain Metastases or Sarcomatoid Disease

October 13th 2022

Focused discussion on brain metastases or sarcomatoid disease in advanced clear cell RCC and the selection of first-line treatment regimens.

Patients With Non–Clear Cell RCC and Sarcomatoid Differentiation Have Inferior Outcomes to Systemic Therapy

October 11th 2022

Patients with non–clear cell renal cell carcinoma and sarcomatoid differentiation experience inferior outcomes to standard systemic therapy compared with those with clear cell disease.

Nivolumab/Ipilimumab Generates Worse Responses in Patients With Metastatic Clear Cell RCC With Low Serum Iron

October 10th 2022

The combination of nivolumab and ipilimumab (Yervoy) was associated with worse clinical benefit in patients with metastatic clear cell renal cell carcinoma who have low serum iron compared with patients with normal/high serum iron.

Tivozanib Improves OS in Long-Term Responders in Relapsed/Refractory, Advanced RCC

October 10th 2022

Tivozanib demonstrated an improvement in overall survival compared with sorafenib in pretreated patients with advanced clear cell renal cell carcinoma, particularly in those who remained progression-free at 1 year and beyond.

Negative Trials Fail to Dampen Enthusiasm for Adjuvant, Combination Therapy in RCC

October 10th 2022

Toni K. Choueiri, MD, provides perspective on key research in renal cell carcinoma, including the first demonstration of benefit with triplet therapy in metastatic clear cell disease, the expansion of HIF-2α inhibition into the first line, and success with VEGF/immune-oncology approaches in the non–clear cell population.

Advanced Clear Cell RCC: Role of Site of Metastases in Selecting First-Line Therapy

October 6th 2022

Shared insight on the importance of sites of metastases and how they may impact first-line treatment selection in advanced clear cell RCC.

Selecting the Appropriate First-Line Therapy in Advanced Clear Cell RCC

October 6th 2022

Centering conversation on systemic therapy, panelists review trial data behind the first-line combination regimens for patients with advanced clear cell RCC.

What is the Role of Nephrectomy in Advanced Clear Cell RCC?

September 29th 2022

Comprehensive insight to the role of nephrectomy over systemic therapy in patients who receive a diagnosis of advanced clear cell RCC.

Overview on Clear Cell Renal Cell Carcinoma: Prevalence and Prognosis

September 29th 2022

Expert oncologists open their discussion on advanced clear cell RCC by identifying its prevalence and prognoses before moving into treatment considerations.

FDA Approves Bevacizumab-adcd Biosimilar in Six Solid Tumors

September 28th 2022

The FDA has approved bevacizumab-adcd, a bevacizumab biosimilar, for the treatment of six types of cancer.